StemoniX opens California site to focus on microOrgan research platform

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Motorion)
(Image: Getty/Motorion)

Related tags: California, Technology, Preclinical contract research, preclinical development, assays, translational sciences, Translational medicine, models

StemoniX opens a new facility in California to house its research team working on its high-throughput microOrgan technology platforms for drug discovery and preclinical development.

MicroOrgans, the technology platform, uses assay plates that contain living microtissues engineered from human induced pluripotent stem cells (hiPSC). According to the company, it is the first ready-to-use platform of this type.

StemoniX also said that microOrgans are designed to enable high-throughput human drug screening without the need for drugs to enter a human body. The platform includes the microBrain and the microHeart to offer the potential to conduct research in these areas at a lower cost by not relying on animal models and human testing.

StemoniX also provides services to its partner organizations to screen compounds and create customized microORgan models and assays tailored to individual discovery and toxicity needs.

According to Ping Yeh, CEO of StemoniX, the company’s microOrgan platform has been used to develop a disease model for Rhett Syndrome as part of a research collaboration agreement with the National institute of Health’s (NIH) National Center for Advancing Translational sciences.

“Our new facility will enable us to build upon these and other innovations involving our microOrgans, while at the same time, fostering collaborations with forward-thinking pharmaceutical and biotech companies,”​ Yeh said in a statement.

Located in La Jolla, the new facility is near facilities for Janssen, Takeda, Vertex, and Celgene and other pharmaceutical companies, as well as biotech research labs.

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 18-Apr-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars